In addition, NRXN3 (a synaptic cell–cell adhesion molecule) occurs at an early stage in Subtype2 (S22D Fig) but later in Subtype1 (S22C Fig) which may suggest an earlier increased AD risk for patients in Subtype2 than the ones in Subtype1. This evidence concerns the gene NRXN3 and Alzheimer disease.